Supplementary Data from Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk NeuroblastomaBalakrishna Koneru(University of California, San Francisco), C. Patrick Reynolds(St. Jude Children's Research Hospital)UnknownMarch 31, 202310.1158/0008-5472.22424632Cited by 0SaveCiteExport RISWatch citationsRelated PapersActivity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo|Blood|2007|155Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines|PLoS ONE|2013|61Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial|Pediatric Blood & Cancer|2018|39